$GROV
Grove Collaborative Holdings, Inc. Stock $grov

$grov Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000184176123000047 Filed on May 11, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$71.57M	$0.00
YoY Change
Cost Of Revenue	$34.31M	$47.74M
YoY Change	-28.13%	-4.57%
Gross Profit	$37.26M	$42.74M
YoY Change	-12.83%	-18.12%
Gross Profit Margin	52.06%
Selling, General & Admin	$38.02M	$83.76M
YoY Change	-54.61%	0.71%
% of Gross Profit	102.06%	196.0%
Research & Development	$4.216M	$6.240M
YoY Change	-32.44%	20.88%
% of Gross Profit	11.32%	14.6%
Depreciation & Amortization	$1.448M	$1.410M
YoY Change	2.7%	25.0%
% of Gross Profit	3.89%	3.3%
Operating Expenses	$42.24M	$1.008M
YoY Change	4089.97%	3584.39%
Operating Profit	-$13.66M	$41.73M
YoY Change	-132.72%	-152640.39%
Interest Expense	$3.729M	-$22.54M
YoY Change	-116.54%	10772.51%
% of Operating Profit		-54.03%
Other Income/Expense, Net	$596.0K	$0.00
YoY Change		-100.0%
Pretax Income	-$13.06M	-$23.55M
YoY Change	-44.55%	3116.02%
Income Tax	$10.00K	$23.00K
% Of Pretax Income
Net Earnings	-$13.07M	-$23.55M
YoY Change	-44.51%	3116.02%
Net Earnings / Revenue	-18.26%
Basic Earnings Per Share	-$0.08	-$5.05
Diluted Earnings Per Share	-$0.08	-$468.1K
COMMON SHARES
Basic Shares Outstanding	168.7M shares	9.387M shares
Diluted Shares Outstanding	168.7M shares	9.387M shares

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$81.65M	$79.82K
YoY Change	102196.42%	-94.4%
Cash & Equivalents	$81.70M	$74.43M
Short-Term Investments
Other Short-Term Assets	$11.66M	$615.3K
YoY Change	1794.3%	-50.55%
Inventory	$40.93M	$50.56M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$134.2M	$695.1K
YoY Change	19211.07%	-73.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.85M	$36.57M
YoY Change	-62.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.817M	$402.6M
YoY Change	-99.3%	15.02%
Total Long-Term Assets	$31.34M	$402.6M
YoY Change	-92.21%	15.43%
TOTAL ASSETS
Total Short-Term Assets	$134.2M	$695.1K
Total Long-Term Assets	$31.34M	$402.6M
Total Assets	$165.6M	$403.3M
YoY Change	-58.94%	14.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.29M	$31.82M
YoY Change	-61.37%
Accrued Expenses	$13.97M	$2.815M
YoY Change	396.19%	122.2%
Deferred Revenue	$9.152M
YoY Change
Short-Term Debt	$0.00	$1.000M
YoY Change	-100.0%
Long-Term Debt Due	$340.0K	$16.72M
YoY Change	-97.97%
Total Short-Term Liabilities	$40.08M	$3.847M
YoY Change	941.96%	203.64%
LONG-TERM LIABILITIES
Long-Term Debt	$69.05M	$0.00
YoY Change
Other Long-Term Liabilities	$28.75M	$50.01M
YoY Change	-42.5%	65.4%
Total Long-Term Liabilities	$69.05M	$50.01M
YoY Change	38.08%	65.4%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.08M	$3.847M
Total Long-Term Liabilities	$69.05M	$50.01M
Total Liabilities	$137.9M	$53.85M
YoY Change	156.03%	79.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$590.9M
YoY Change
Common Stock	$18.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.70M	-$498.9M
YoY Change
Total Liabilities & Shareholders Equity	$165.6M	$403.3M
YoY Change	-58.94%	14.75%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$13.07M	-$23.55M
YoY Change	-44.51%	3116.02%
Depreciation, Depletion And Amortization	$1.448M	$1.410M
YoY Change	2.7%	25.0%
Cash From Operating Activities	-$6.737M	-$427.4K
YoY Change	1476.24%	8448.2%
INVESTING ACTIVITIES
Capital Expenditures	$784.0K	-$1.352M
YoY Change	-157.99%	7.13%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$784.0K	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$235.0K	$275.0K
YoY Change	-14.55%
Cash From Financing Activities	$1.990M	0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-$6.737M	-427.4K
Cash From Investing Activities	-$784.0K	0.000
Cash From Financing Activities	$1.990M	0.000
Net Change In Cash	-$5.531M	-427.4K
YoY Change	1194.07%	-130.0%
FREE CASH FLOW
Cash From Operating Activities	-$6.737M	-$427.4K
Capital Expenditures	$784.0K	-$1.352M
Free Cash Flow	-$7.521M	$924.6K
YoY Change	-913.44%	-26.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001841761
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-40263
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Grove Collaborative Holdings, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-2840659
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1301 Sansome Street
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94111
CY2023Q1	dei	City Area Code CityAreaCode	800
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	231-8527
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81653000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81084000	usd
CY2023Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	5850000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	11950000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	40930000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	44132000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5806000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4844000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	134239000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	142010000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2951000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2951000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13852000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14530000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11721000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12362000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2817000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2192000	usd
CY2023Q1	us-gaap	Assets Assets	165580000	usd
CY2022Q4	us-gaap	Assets Assets	174045000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	12293000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10712000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13967000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31354000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9152000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10878000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3762000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3705000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	565000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	249000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	340000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	575000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	40079000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	57473000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	69049000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	60620000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15233000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16192000	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	13519000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	13227000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	137880000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	147512000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	18000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	618609000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	604373000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-590927000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-577858000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	27700000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26533000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165580000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	174045000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	71565000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90479000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	34310000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	47742000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	37255000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	42737000	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	8673000	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	32793000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4216000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6240000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38021000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	50970000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-13655000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-47266000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3729000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	2087000	usd
CY2023Q1	grov	Fair Value Adjustment Of Warrants Additional Shares Liability FairValueAdjustmentOfWarrantsAdditionalSharesLiability	223000	usd
CY2022Q1	grov	Fair Value Adjustment Of Warrants Additional Shares Liability FairValueAdjustmentOfWarrantsAdditionalSharesLiability	0	usd
CY2023Q1	grov	Fair Value Adjustment Of Earn Out Liability FairValueAdjustmentOfEarnOutLiability	143000	usd
CY2022Q1	grov	Fair Value Adjustment Of Earn Out Liability FairValueAdjustmentOfEarnOutLiability	0	usd
CY2023Q1	grov	Fair Value Adjustment Of Warrants Public And Private FairValueAdjustmentOfWarrantsPublicAndPrivate	-674000	usd
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.05
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	168739298	shares
CY2022Q1	grov	Fair Value Adjustment Of Warrants Public And Private FairValueAdjustmentOfWarrantsPublicAndPrivate	0	usd
CY2023Q1	grov	Fair Value Adjustment Of Derivative Instrument FairValueAdjustmentOfDerivativeInstrument	600000	usd
CY2022Q1	grov	Fair Value Adjustment Of Derivative Instrument FairValueAdjustmentOfDerivativeInstrument	0	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4617000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1992000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	596000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-95000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13059000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-47361000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13069000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-47384000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.05
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	168739298	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9387142	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9387142	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26533000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	68000	usd
CY2023Q1	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-356000	usd
CY2023Q1	grov	Adjustments To Additional Paid In Capital Reduction Of Transaction Costs AdjustmentsToAdditionalPaidInCapitalReductionOfTransactionCosts	9609000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4915000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13069000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	27700000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-456279000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	171000	usd
CY2022Q1	grov	Adjustments To Additional Paid In Capital Early Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalEarlyExerciseOfStockOptions	125000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4501000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-47384000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-498866000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-13069000	usd
CY2022Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	8000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3078000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3038000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-47384000	usd
CY2023Q1	grov	Adjustment Of Convertible Preferred Stock Warrant Liability AdjustmentOfConvertiblePreferredStockWarrantLiability	0	usd
CY2022Q1	grov	Adjustment Of Convertible Preferred Stock Warrant Liability AdjustmentOfConvertiblePreferredStockWarrantLiability	-1886000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4893000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4460000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1448000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1410000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	292000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023Q1	grov	Adjustments To Transaction Costs Derivative Instrument Reverse Recapitalization AdjustmentsToTransactionCostsDerivativeInstrumentReverseRecapitalization	-3745000	usd
CY2022Q1	grov	Adjustments To Transaction Costs Derivative Instrument Reverse Recapitalization AdjustmentsToTransactionCostsDerivativeInstrumentReverseRecapitalization	0	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	948000	usd
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	195000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	124000	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	856000	usd
CY2023Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	77000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-784000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1352000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	828000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3312000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1554000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10287000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	162000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2917000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1726000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	159000	usd
CY2023Q1	grov	Increase Decrease In Operating Right Of Use Asset IncreaseDecreaseInOperatingRightOfUseAsset	261000	usd
CY2022Q1	grov	Increase Decrease In Operating Right Of Use Asset IncreaseDecreaseInOperatingRightOfUseAsset	22000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	316000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-229000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6737000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29503000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	784000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1352000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95985000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78376000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90454000	usd
CY2023Q1	grov	Proceeds From Issuance Of Redeemable Convertible Common Stock ProceedsFromIssuanceOfRedeemableConvertibleCommonStock	0	usd
CY2022Q1	grov	Proceeds From Issuance Of Redeemable Convertible Common Stock ProceedsFromIssuanceOfRedeemableConvertibleCommonStock	27500000	usd
CY2023Q1	grov	Payment Of Transaction Costs Reverse Recapitalization PaymentOfTransactionCostsReverseRecapitalization	4150000	usd
CY2022Q1	grov	Payment Of Transaction Costs Reverse Recapitalization PaymentOfTransactionCostsReverseRecapitalization	489000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	7500000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	837000	usd
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	235000	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	275000	usd
CY2023Q1	grov	Proceeds From Issuance Of Shares Payments Of Tax Withholding Share Based Payment Arrangement ProceedsFromIssuanceOfSharesPaymentsOfTaxWithholdingShareBasedPaymentArrangement	-288000	usd
CY2022Q1	grov	Proceeds From Issuance Of Shares Payments Of Tax Withholding Share Based Payment Arrangement ProceedsFromIssuanceOfSharesPaymentsOfTaxWithholdingShareBasedPaymentArrangement	171000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1990000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26907000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5531000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3948000	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	74428000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9000	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	21000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	2734000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1461000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	113000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	286000	usd
CY2023Q1	grov	Adjustments To Additional Paid In Capital Reduction Of Transaction Costs AdjustmentsToAdditionalPaidInCapitalReductionOfTransactionCosts	9609000	usd
CY2022Q1	grov	Adjustments To Additional Paid In Capital Reduction Of Transaction Costs AdjustmentsToAdditionalPaidInCapitalReductionOfTransactionCosts	0	usd
CY2023Q1	grov	Transaction Costs Incurred But Not Yet Paid TransactionCostsIncurredButNotYetPaid	0	usd
CY2022Q1	grov	Transaction Costs Incurred But Not Yet Paid TransactionCostsIncurredButNotYetPaid	2582000	usd
CY2023Q1	grov	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	0	usd
CY2022Q1	grov	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	125000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81653000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74428000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	8801000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90454000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	74428000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grove Collaborative Holdings, Inc., a public benefit corporation, (formerly known as Virgin Group Acquisition Corp. II, or “VGAC II”) and its wholly owned subsidiaries (collectively, the “Company” or “Grove”) is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with an environmental focus and headquartered in San Francisco, California. In the United States, the Company sells its products through two channels: a direct-to-consumer (“DTC”) platform at www.grove.co and the Company’s mobile applications, where the Company sells products from Grove-owned brands (“Grove Brands”) and third-parties, and the retail channel into which the Company sell products from Grove-owned brands at wholesale. The Company develops and sells natural products that are free from the harmful chemicals identified in the Company’s “anti-ingredient” list and designs form factors and product packaging that reduces plastic waste and improves the environmental impact of the categories in which the Company operates. The Company also purchases environmental offsets that have made it the first plastic neutral retailer in the world. Grove Collaborative, Inc. (herein referred to as “Legacy Grove”), the Company’s accounting predecessor, was incorporated in Delaware in 2016.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022 (the “Closing Date”), the Company consummated the previously-announced transactions contemplated by the Agreement and Plan of Merger, dated December 7, 2021, amended and restated on March 31, 2022 (the “Merger Agreement”), among Virgin Group Acquisition Corp. II, a blank check company incorporated as a Cayman Islands exempt company in 2020 (“VGAC II”), Treehouse Merger Sub, Inc. (“VGAC II Merger Sub I”), Treehouse Merger Sub II, LLC (“VGAC II Merger Sub II”), and Legacy Grove (“the Merger”). In connection with the Merger, VGAC II changed its jurisdiction of incorporation from the Cayman Islands to the State of Delaware and changed its name to Grove Collaborative Holdings, Inc (the “Domestication”), a public benefit corporation. On the Closing Date, VGAC Merger Sub II merged with and into Legacy Grove with Legacy Grove being the surviving corporation and a wholly-owned subsidiary of the Company (the “Initial Merger”), and, immediately following the Initial Merger, and as part of the same overall transaction as the Initial Merger, Legacy Grove merged with and into VGAC Merger Sub II, the separate corporate existence of Legacy Grove ceased, and Merger Sub II continued as the surviving company and a wholly-owned subsidiary of the Company and changed its name to Grove Collaborative, Inc.(together with the Merger and the Domestication, the “Business Combination”).</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Business Combination is accounted for as a reverse recapitalization with Legacy Grove being the accounting acquirer and VGAC II as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the unaudited condensed consolidated financial statements represents the accounts of Legacy Grove. The shares and net loss per common share prior to the Closing have been retroactively restated as shares reflecting the exchange ratio established in the Closing.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Business Combination, VGAC II’s public shares, and public warrants were listed on the New York Stock Exchange (“NYSE”) under the symbols “VGII” and “VGII.WS,” respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 17, 2022, the Company's Class A common stock and public warrants began trading on (“NYSE”), under the symbols “GROV” and “GROV.WS,” respectively. See Note 7,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Common Stock and Warrants</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details.</span></div>
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-590900000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81700000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. These estimates made by management include the determination of reserves amounts for the Company’s inventories on hand, useful life of intangible assets, sales returns and allowances and certain assumptions used in the valuation of equity awards, the estimated fair value of common stock liability classified Public and Private Placement Warrants, the fair value of Earn-Out liabilities, the fair value of Additional Shares liabilities, the fair value of the Structural Derivative Liability and stock based compensation expense. Actual results could differ from those estimates, and such estimates could be material to the Company’s financial position and the results of operations.</span></div>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains the majority of its cash, cash equivalents and restricted cash in accounts with one financial institution within the United States, generally in the form of demand accounts. Deposits in this institution may exceed federally insured limits. Management believes minimal credit risk exists with respect to this financial institution and the Company has not experienced any losses on such amounts.</span></div>
CY2023Q1	grov	Revenue From Contract With Customer Complementary Membership Period RevenueFromContractWithCustomerComplementaryMembershipPeriod	P60D
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	71565000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90479000	usd
CY2023Q1	grov	Fulfillment Costs FulfillmentCosts	17000000	usd
CY2022Q1	grov	Fulfillment Costs FulfillmentCosts	24400000	usd
CY2023Q1	grov	Inventory Purchases Current InventoryPurchasesCurrent	2530000	usd
CY2022Q4	grov	Inventory Purchases Current InventoryPurchasesCurrent	2757000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2861000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1714000	usd
CY2023Q1	us-gaap	Accrued Advertising Current AccruedAdvertisingCurrent	1020000	usd
CY2022Q4	us-gaap	Accrued Advertising Current AccruedAdvertisingCurrent	1203000	usd
CY2023Q1	grov	Accrued Fulfillment Costs Current AccruedFulfillmentCostsCurrent	1335000	usd
CY2022Q4	grov	Accrued Fulfillment Costs Current AccruedFulfillmentCostsCurrent	1725000	usd
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1509000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1374000	usd
CY2023Q1	grov	Transaction Costs Current TransactionCostsCurrent	0	usd
CY2022Q4	grov	Transaction Costs Current TransactionCostsCurrent	17500000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4712000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5081000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13967000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31354000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	69389000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	61195000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	340000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	575000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	69049000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	60620000	usd
CY2023Q1	grov	Fair Value Adjustment Of Derivative Instrument FairValueAdjustmentOfDerivativeInstrument	600000	usd
CY2023Q1	us-gaap	Purchase Obligation PurchaseObligation	15300000	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	18700000	usd
CY2022Q2	grov	Reverse Recapitalization Percentage Of Voting Interests Acquired ReverseRecapitalizationPercentageOfVotingInterestsAcquired	1
CY2022Q2	grov	Proceed From Issuance Of Common Stock Reverse Recapitalization ProceedFromIssuanceOfCommonStockReverseRecapitalization	97100000	usd
CY2022Q2	grov	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	24400000	usd
CY2022Q4	grov	Transaction Costs Current TransactionCostsCurrent	17500000	usd
CY2023Q1	grov	Increase Decrease In Accrued Transaction Costs Current IncreaseDecreaseInAccruedTransactionCostsCurrent	-13400000	usd
CY2023Q1	grov	Increase Decrease To Other Nonoperating Income Expense IncreaseDecreaseToOtherNonoperatingIncomeExpense	3800000	usd
CY2023Q1	grov	Adjustments To Additional Paid In Capital Reduction Of Transaction Costs AdjustmentsToAdditionalPaidInCapitalReductionOfTransactionCosts	9600000	usd
CY2023Q1	grov	Shares Issued Shares Derivative Instrument Contingent Consideration Canceled SharesIssuedSharesDerivativeInstrumentContingentConsiderationCanceled	985722	shares
CY2022Q2	grov	Reverse Recapitalization Contingent Consideration Earnout Period ReverseRecapitalizationContingentConsiderationEarnoutPeriod	P10Y
CY2022Q4	grov	Consulting Fee Expense ConsultingFeeExpense	150000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10521571	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.59
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M13D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	61000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	178564	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.38
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	170516	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.82
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10172491	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.59
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	98000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	9040393	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.32
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y6M29D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	98000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	100000	usd
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4400000	usd
CY2023Q1	grov	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue	0	usd
CY2022Q1	grov	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAggregateIntrinsicValue	400000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4900000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4500000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	28600000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	72435528	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	148393189	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
grov-20230331_def.xml	Edgar Link	unprocessable
0001841761-23-000047-index-headers.html	Edgar Link	pending
0001841761-23-000047-index.html	Edgar Link	pending
0001841761-23-000047.txt	Edgar Link	pending
0001841761-23-000047-xbrl.zip	Edgar Link	pending
exhibit1032groveformofperf.htm	Edgar Link	pending
exhibit1034structural-amen.htm	Edgar Link	pending
exhibit311q12023.htm	Edgar Link	pending
exhibit312q12023.htm	Edgar Link	pending
exhibit321q12023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
grov-20230331.htm	Edgar Link	pending
grov-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
grov-20230331_cal.xml	Edgar Link	unprocessable
grov-20230331_lab.xml	Edgar Link	unprocessable
grov-20230331_pre.xml	Edgar Link	unprocessable
grov-20230331_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GROV
Grove Collaborative Holdings, Inc. Stock $grov

2023 Q1 Form 10-Q Financial Statement

#000184176123000047 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GROV Grove Collaborative Holdings, Inc. Stock $grov

2023 Q1 Form 10-Q Financial Statement

#000184176123000047 Filed on May 11, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GROV
Grove Collaborative Holdings, Inc. Stock $grov